Table 2.
Characteristics of the 28 studies included for analysis
| Category | Details | Number of Articles | |
|---|---|---|---|
| Year of Publication | 2017 | 5 | |
| 2018 | 5 | ||
| 2019 | 2 | ||
| 2020 | 4 | ||
| 2021 | 7 | ||
| 2022 | 5 | ||
| Countries Studieda | United States of America | 9 | |
| United Kingdom | 4 | ||
| Germany | 4 | ||
| Singapore | 3 | ||
| Netherlands | 3 | ||
| Canada | 1 | ||
| China | 1 | ||
| Denmark | 1 | ||
| Italy | 1 | ||
| Japan | 1 | ||
| Portugal | 1 | ||
| Spain | 1 | ||
| Taiwan | 1 | ||
| Type of Study | Quantitative | Experimental | 6 |
| Meta-Analysis | 1 | ||
| Observational | 12 | ||
| Randomized Clinical Trials | 3 | ||
| Qualitative | Case Study | 1 | |
| Guideline | 2 | ||
| Interviews | 2 | ||
| Report | 1 | ||
| Type of Dementia | Dementia | 22 | |
| MCI and dementia | 3 | ||
| AD | 2 | ||
| MCI | 1 | ||
| Comorbidities Studiedb | Depression | 8 | |
| Hypertension | 7 | ||
| Cardiovascular | 7 | ||
| General “comorbidities” | 7 | ||
| Diabetes | 6 | ||
| Stroke | 5 | ||
| Auditory Impairment | 4 | ||
| Other (e.g. dyslipidemia, osteoarticular diseases) | 2 | ||
| Kidney Disease | 1 | ||
| Visual Impairment | 1 | ||
| Categories and Subcategories | Risk assessment and prevention | 15 | |
| Screening, diagnosis, and detection | 4 | ||
| Management | 9 | ||
| Tools and technologies | 15 | ||
| Recommendations for clinical practice | 10 | ||
| Programs and initiatives | 3 | ||
aSome articles are representative of data from multiple countries
bSome articles focus on multiple comorbidities